These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34756573)

  • 21. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
    Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O
    Front Public Health; 2022; 10():816848. PubMed ID: 35372242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
    Joyner MJ; Carter RE; Senefeld JW; Klassen SA; Mills JR; Johnson PW; Theel ES; Wiggins CC; Bruno KA; Klompas AM; Lesser ER; Kunze KL; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; van Helmond N; Verdun NC; Marks P; van Buskirk CM; Winters JL; Stubbs JR; Rea RF; Hodge DO; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Buras MR; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Paneth NS; Fairweather D; Wright RS; Casadevall A
    N Engl J Med; 2021 Mar; 384(11):1015-1027. PubMed ID: 33523609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
    Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
    Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions.
    Bonetti TCS; Latini FRM; Invitti AL; Fonseca MCM; Scorza FA; Saldanha MG; Bellucco FT; Bacarov NBS; Soane MM; Girão MJBC
    Clinics (Sao Paulo); 2021; 76():e2818. PubMed ID: 34468538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishing the First COVID-19 Convalescent Plasma Biobank in Jordan.
    Souan L; Sughayer MA; Abu Alhowr MM
    Biopreserv Biobank; 2022 Oct; 20(5):423-428. PubMed ID: 35904406
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
    Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
    Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
    Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
    Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
    Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
    Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children.
    Gordon O; Brosnan MK; Yoon S; Jung D; Littlefield K; Ganesan A; Caputo CA; Li M; Morgenlander WR; Henson SN; Ordonez AA; De Jesus P; Tucker EW; Peart Akindele N; Ma Z; Wilson J; Ruiz-Bedoya CA; Younger MEM; Bloch EM; Shoham S; Sullivan D; Tobian AA; Cooke KR; Larman B; Gobburu JV; Casadevall A; Pekosz A; Lederman HM; Klein SL; Jain SK
    JCI Insight; 2022 Jan; 7(2):. PubMed ID: 34855624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
    Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
    Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.